SI3768284T1 - Sestavki iz flagelina enterococcusa za uporabo v terapiji - Google Patents

Sestavki iz flagelina enterococcusa za uporabo v terapiji

Info

Publication number
SI3768284T1
SI3768284T1 SI201930190T SI201930190T SI3768284T1 SI 3768284 T1 SI3768284 T1 SI 3768284T1 SI 201930190 T SI201930190 T SI 201930190T SI 201930190 T SI201930190 T SI 201930190T SI 3768284 T1 SI3768284 T1 SI 3768284T1
Authority
SI
Slovenia
Prior art keywords
flagellin
enterococcus
therapy
compositions
enterococcus flagellin
Prior art date
Application number
SI201930190T
Other languages
English (en)
Slovenian (sl)
Inventor
Imke Elisabeth MULDER
Emma Raftis
Emma Elizabeth Clare Hennessy
Delphine Louise Claudette Laute-Caly
Philip Cowie
Original Assignee
4D Pharma Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1804384.4A external-priority patent/GB201804384D0/en
Priority claimed from GBGB1809953.1A external-priority patent/GB201809953D0/en
Priority claimed from GBGB1811900.8A external-priority patent/GB201811900D0/en
Priority claimed from GBGB1812378.6A external-priority patent/GB201812378D0/en
Priority claimed from GBGB1813444.5A external-priority patent/GB201813444D0/en
Priority claimed from GBGB1813423.9A external-priority patent/GB201813423D0/en
Priority claimed from GBGB1816834.4A external-priority patent/GB201816834D0/en
Priority claimed from GBGB1817641.2A external-priority patent/GB201817641D0/en
Priority claimed from GBGB1901218.6A external-priority patent/GB201901218D0/en
Priority claimed from GBGB1901199.8A external-priority patent/GB201901199D0/en
Priority claimed from GBGB1901992.6A external-priority patent/GB201901992D0/en
Priority claimed from GBGB1901993.4A external-priority patent/GB201901993D0/en
Application filed by 4D Pharma Research Limited filed Critical 4D Pharma Research Limited
Publication of SI3768284T1 publication Critical patent/SI3768284T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SI201930190T 2018-03-19 2019-03-19 Sestavki iz flagelina enterococcusa za uporabo v terapiji SI3768284T1 (sl)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GBGB1804384.4A GB201804384D0 (en) 2018-03-19 2018-03-19 Compositions
GBGB1809953.1A GB201809953D0 (en) 2018-06-18 2018-06-18 Compositions
EP18178350 2018-06-18
GBGB1811900.8A GB201811900D0 (en) 2018-07-20 2018-07-20 Compositions comprising bacterial strains
GBGB1812378.6A GB201812378D0 (en) 2018-07-30 2018-07-30 Compositions comprising bacterial strains
GBGB1813444.5A GB201813444D0 (en) 2018-08-17 2018-08-17 Compositions
GBGB1813423.9A GB201813423D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GBGB1816834.4A GB201816834D0 (en) 2018-10-16 2018-10-16 Compositions
GBGB1817641.2A GB201817641D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GBGB1901218.6A GB201901218D0 (en) 2019-01-29 2019-01-29 Compositions
GBGB1901199.8A GB201901199D0 (en) 2019-01-29 2019-01-29 Compositions comprising bacterial strains
GBGB1901992.6A GB201901992D0 (en) 2019-02-13 2019-02-13 Compositions comprising bacterial strains
GBGB1901993.4A GB201901993D0 (en) 2019-02-13 2019-02-13 Compositions
EP19714132.8A EP3768284B1 (en) 2018-03-19 2019-03-19 Compositions of entrecoccus flagellin for use in therapy
PCT/EP2019/056809 WO2019180000A1 (en) 2018-03-19 2019-03-19 Compositions

Publications (1)

Publication Number Publication Date
SI3768284T1 true SI3768284T1 (sl) 2022-04-29

Family

ID=65955185

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930190T SI3768284T1 (sl) 2018-03-19 2019-03-19 Sestavki iz flagelina enterococcusa za uporabo v terapiji

Country Status (25)

Country Link
US (3) US11419931B2 (https=)
EP (3) EP3768284B1 (https=)
JP (3) JP2021518414A (https=)
KR (2) KR20210003096A (https=)
CN (2) CN112004543A (https=)
AU (2) AU2019238358A1 (https=)
BR (2) BR112020019008A2 (https=)
CA (2) CA3094297A1 (https=)
CY (1) CY1125104T1 (https=)
DK (1) DK3768284T3 (https=)
ES (1) ES2908826T3 (https=)
HR (1) HRP20220368T1 (https=)
HU (1) HUE058151T2 (https=)
IL (2) IL277422A (https=)
LT (1) LT3768284T (https=)
MA (1) MA52128A (https=)
MD (1) MD3768284T2 (https=)
MX (2) MX2020009736A (https=)
PL (1) PL3768284T3 (https=)
RS (1) RS63090B1 (https=)
SG (2) SG11202009254YA (https=)
SI (1) SI3768284T1 (https=)
SM (1) SMT202200111T1 (https=)
TW (2) TW202003001A (https=)
WO (2) WO2019180051A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
US20230022045A1 (en) * 2019-12-03 2023-01-26 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
US12350300B2 (en) 2021-10-08 2025-07-08 Iowa State University Research Foundation, Inc. Use of dopamine producing products to increase vaccine efficacy
CN113999923B (zh) * 2021-11-25 2024-05-14 上海金翌生物科技有限公司 小柳-原田综合症标志微生物及其应用
CN115287243B (zh) * 2022-04-15 2023-06-06 集美大学 一株变形假单胞菌flgK基因沉默菌株及其构建方法
JPWO2024096122A1 (https=) * 2022-11-04 2024-05-10
KR102878250B1 (ko) 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20080025977A1 (en) 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
CN101595133B (zh) 2006-10-27 2012-11-14 比利时胶囊公司 羟丙基甲基纤维素硬胶囊及制备方法
EP1958647A1 (en) 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
DK2133092T3 (en) * 2007-03-19 2016-01-11 Morishita Jintan Co Oral vaccine
BRPI0911604A2 (pt) * 2008-04-25 2015-12-15 Inst Systems Biology vacinas de polipeptídeo de flagelina
CA2777198C (en) * 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
WO2012097012A1 (en) 2011-01-10 2012-07-19 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US10786637B2 (en) 2011-07-13 2020-09-29 Pharmaxis Ltd. Delivery devices
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
FR2989002B1 (fr) 2012-04-10 2015-05-15 Beepratte Lab Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique
CA2884816A1 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3104885A4 (en) * 2014-02-12 2017-08-30 Transalgae (Israel) Ltd Algal based edible vaccines
GB201520502D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3630942B1 (en) * 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
MX392976B (es) 2017-08-10 2025-03-24 4D Pharma Res Limited Composiciones que comprenden cepas bacterianas.
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains

Also Published As

Publication number Publication date
SMT202200111T1 (it) 2022-05-12
US11857614B2 (en) 2024-01-02
JP2021518129A (ja) 2021-08-02
KR20210003096A (ko) 2021-01-11
CA3094297A1 (en) 2019-09-26
DK3768284T3 (da) 2022-03-07
HRP20220368T1 (hr) 2022-06-24
CA3094139A1 (en) 2019-09-26
KR20200134255A (ko) 2020-12-01
US20210169950A1 (en) 2021-06-10
IL277421A (en) 2020-11-30
US20220257745A1 (en) 2022-08-18
BR112020018818A2 (pt) 2021-05-04
WO2019180051A1 (en) 2019-09-26
BR112020019008A2 (pt) 2020-12-29
WO2019180000A1 (en) 2019-09-26
CN112004543A (zh) 2020-11-27
AU2019239048B2 (en) 2022-07-21
PL3768284T3 (pl) 2022-04-11
JP2021518414A (ja) 2021-08-02
SG11202009254YA (en) 2020-10-29
EP3768284A1 (en) 2021-01-27
TW202003000A (zh) 2020-01-16
MX2020009733A (es) 2022-10-27
TW202003001A (zh) 2020-01-16
SG11202009259VA (en) 2020-10-29
JP2023100747A (ja) 2023-07-19
IL277422A (en) 2020-11-30
EP3768285A1 (en) 2021-01-27
EP3768284B1 (en) 2022-01-05
EP4046644A1 (en) 2022-08-24
ES2908826T3 (es) 2022-05-04
RS63090B1 (sr) 2022-04-29
IL277421B (en) 2022-04-01
MA52128A (fr) 2021-01-27
HUE058151T2 (hu) 2022-07-28
AU2019238358A1 (en) 2020-10-08
CY1125104T1 (el) 2024-02-16
LT3768284T (lt) 2022-04-11
AU2019239048A1 (en) 2020-11-05
KR102578117B1 (ko) 2023-09-12
MX2020009736A (es) 2021-01-08
US11419931B2 (en) 2022-08-23
CN111886018A (zh) 2020-11-03
MD3768284T2 (ro) 2022-06-30
US20210138058A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
SI3768284T1 (sl) Sestavki iz flagelina enterococcusa za uporabo v terapiji
IL282487A (en) Tyk2 inhibitors and uses thereof
DK3902547T3 (da) Csf1r-hæmmere til anvendelse i cancerbehandling
IL282663A (en) Bt1718 for use in treating cancer
SI3429571T1 (sl) Kombinacije zaviralcev LSD1 za uporabo pri zdravljenju neoplastičnih bolezni
SI3368069T1 (sl) Uporaba zaviralcev miostatina in kombinirane terapije
DK3350157T3 (da) Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
SI3258962T1 (sl) Mešane sestave alergenov in postopki za njihovo uporabo
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
HRP20251604T1 (hr) Antagonist gremlina‑1 za upotrebu u liječenju raka
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
SI3962601T1 (sl) Agonisti 5-HT2A za uporabo pri zdravljenju depresije
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
EP3860585A4 (en) Therapeutic compositions
EP3868385C0 (en) GASTRIC CANCER TREATMENT COMPOSITION COMPRISING A SYT11 INHIBITOR AS THE ACTIVE INGREDIENT
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
IL269884B1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
EP3203995A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
IL284981A (en) Semaphorin-4d antagonists for use in cancer therapy
SI3373922T1 (sl) Sestavki in postopki za uporabo pri zdravljenju homocistinurije
SI3697399T1 (sl) Terapevtska sredstva za uporabo pri zdravljenju sindroma nemirnih nog